Why Did Amazon Remove nmn Supplements? The FDA Timeline Explained
Information checked November 2, 2026.
Amazon’s 2023 restriction on NMN supplements followed a then-current FDA interpretation of the federal dietary-supplement definition. In September 2025, the FDA revised that interpretation and concluded that NMN is not excluded from the dietary-supplement definition under the specific drug-preclusion clause it had previously applied. These are two separate events: an FDA interpretation does not automatically reinstate every Amazon listing, and it does not approve every NMN product for safety or effectiveness.[1][2]
The distinction matters because the older version of this article described NMN as having been reclassified as a drug due to evidence of longevity benefits, said NMN was still unavailable on major platforms, and promoted AIDEVI products. Those statements blurred legal status, retailer policy, product safety, and health claims. This update separates them and focuses on what the public record supports.
This image refers to the 2023 marketplace event; see the updated FDA timeline below.
The short version is that Amazon’s seller notice cited the FDA’s 2022 position and set a platform requirement for NMN listings. The FDA’s 2025 response later changed its interpretation of one legal exclusion clause. That response did not amount to premarket approval of NMN supplements or a guarantee that any particular product is safe, compliant, or eligible to sell on Amazon.
What happened: the NMN and Amazon timeline
| Date | What the record says | What it means |
|---|---|---|
| November 2022 | The FDA told an NMN notifier that it considered NMN excluded from the dietary-supplement definition under the drug-preclusion provision. | This was a legal interpretation of the ingredient’s status under a specific clause, not a finding that NMN had been proven to extend life. |
| February–March 2023 | Amazon’s Restricted Products team notified sellers that NMN products could not continue to be sold as dietary supplements on the platform under the FDA position it cited. The notice set March 13, 2023 as the deadline and described an NDC and reinstatement process for products sellers sought to offer as approved over-the-counter drugs. | Amazon applied its own marketplace requirements to affected listings. The notice was not a clinical review of every NMN product on Amazon. |
| September 29, 2025 | In response to a citizen petition, the FDA revised its interpretation and concluded that NMN is not excluded under section 201(ff)(3)(B) of the Federal Food, Drug, and Cosmetic Act. | The FDA’s later position changed the earlier drug-preclusion analysis. It did not decide that every NMN product meets all legal, labeling, and safety requirements. |
Why did Amazon remove NMN from its marketplace?
The seller notice circulated by Amazon’s Restricted Products team said that the FDA had announced on November 4, 2022 that NMN was no longer considered a dietary supplement. Amazon then told sellers that products containing NMN could not be sold or distributed as dietary supplements in the United States and required a drug approval pathway, including a National Drug Code, for the listings it described. The notice allowed continued offers until March 13, 2023 and set out steps for sellers seeking reinstatement.[1]
That notice explains the platform’s stated reason at the time: Amazon relied on the FDA’s then-current interpretation when setting its listing requirements. It does not establish that Amazon independently determined that every NMN product was unsafe, nor does it establish that the FDA had concluded NMN was effective for longevity. A classification decision and a product-specific safety or efficacy finding are different questions.
The restriction was about NMN products listed as dietary supplements on Amazon’s U.S. marketplace. It should not be rewritten as a worldwide ban covering every retailer, country, or product category. Retailer terms and listing eligibility can differ by marketplace and change over time.
The article keeps this original image as historical context rather than as a statement about current listing status.
What changed in the FDA’s 2025 response?
On September 29, 2025, the FDA responded to a citizen petition from the Natural Products Association and the Alliance for Natural Health USA. The agency reconsidered its interpretation of the “race-to-market” provision in section 201(ff)(3)(B). It concluded that NMN is not excluded from the dietary-supplement definition under that provision because the agency was aware of evidence that NMN had been marketed as a dietary supplement in the United States as early as 2017, before NMN was authorized for investigation as a new drug.[2]
In plain language, the FDA changed its answer to a particular legal question: whether the drug-preclusion clause automatically excluded NMN from the dietary-supplement definition based on the timing of drug investigation and prior U.S. marketing. The FDA said its earlier interpretation did not reflect the best reading of the statute and amended its prior determination.
The scope of that conclusion matters. The FDA did not say that every product containing NMN automatically qualifies as a dietary supplement. It noted that it would continue to examine whether a particular product was marketed in the United States and is actually a dietary supplement or food. A product must still meet the other parts of the legal definition and comply with applicable requirements. The letter also explains that an ingredient’s status under the drug-preclusion clause is not itself a safety determination.[2]
Does the FDA’s 2025 response mean NMN is FDA-approved?
No. The FDA does not approve dietary supplements for safety and effectiveness before they are marketed, and the agency’s 2025 response did not grant an approval for NMN products. Under the FDA’s general explanation of supplement oversight, manufacturers are responsible for ensuring that their products are safe and properly labeled; the FDA can take action against products that are unsafe or otherwise violate the law. Certain new dietary ingredients also have a separate notification requirement.[3]
The FDA response is best described as a revised interpretation of one exclusion provision—not as a blanket endorsement of a supplement, a finding that a product is safe for every consumer, or proof that a product’s health claims are true. Similarly, a seller’s NDI notification or an FDA acknowledgement of a notification should not be described as FDA approval. The agency’s 2025 letter says its earlier acknowledgement of an NDI notification was procedural and did not constitute a finding that the ingredient or the specific supplement was safe.[2]
Avoid claims that FDA “approved NMN for anti-aging,” “confirmed NMN is safe,” or “banned NMN because it works.” None of those statements accurately summarizes the cited agency records. The FDA’s dietary-supplement status analysis is not a clinical trial and does not prove that NMN slows aging, prevents disease, or improves a particular health outcome.
Did NMN automatically return to Amazon after the FDA response?
The FDA’s response changed the agency’s interpretation; it did not itself reinstate an Amazon ASIN or order Amazon to approve a seller. Amazon controls its own catalog, seller eligibility, documentation requests, and product-listing decisions. It is therefore important to check the current Amazon U.S. listing and the current seller policy rather than relying on a 2023 email, a dated blog post, or a search result from another country.
For a particular product, check whether the listing is actually available to ship to your location, who the seller is, whether the label identifies all ingredients and amounts, and whether the listing makes disease-treatment or guaranteed longevity claims. Marketplace availability can change by seller, product, location, and account. A listing appearing online is not proof that the FDA has approved it or independently verified its claims.
If you are a seller, use the current Seller Central rules and the notice attached to your own account. The 2023 reinstatement instructions described a pathway for the policy conditions then in effect; do not assume those instructions still govern a current listing without checking Amazon’s latest requirements.[4]
What the old article should no longer claim
- “The FDA reclassified NMN as a drug because studies proved longevity benefits.” The 2022 position concerned the statutory drug-preclusion clause and an investigational new drug; it was not a conclusion that NMN had proven longevity benefits.
- “The FDA declared NMN safe” or “there are no safety concerns.” The 2025 letter revised the exclusion analysis and separately discussed safety and product-specific requirements. It did not approve every NMN supplement.
- “NMN is still unavailable on Amazon and other major platforms.” This is a time-sensitive listing claim. The old statement was published before the FDA’s 2025 response and should not be repeated as a current fact without checking a specific marketplace and listing.
- “NMN reverses aging” or “users regain youthful vitality.” The policy history does not substantiate these health outcomes. Remove testimonials and promotional claims that do not have adequate evidence and appropriate qualification.
Frequently asked questions
Was NMN banned by the FDA?
The FDA’s 2022 position treated NMN as excluded from the dietary-supplement definition under a drug-preclusion provision. In September 2025, the agency amended that interpretation and concluded that NMN is not excluded under that provision. That is more precise than saying the FDA “banned NMN.”
Why did Amazon remove NMN products in 2023?
Amazon’s seller notice cited the FDA’s then-current position and required sellers to meet the platform’s stated requirements. The notice gave March 13, 2023 as the deadline for continuing offers under its process. It explains Amazon’s marketplace action at that time; it is not evidence that all NMN products were individually tested by Amazon.
Does the 2025 FDA update guarantee NMN products are safe?
No. The agency revised its interpretation of a legal exclusion clause. It did not make a blanket safety finding for every NMN product, manufacturer, serving size, or consumer.
Can I buy NMN on Amazon now?
Availability depends on the current marketplace, seller, listing, and delivery location. Check the live Amazon U.S. listing and its seller details. The FDA’s response by itself does not confirm that a particular product is listed, eligible, or endorsed by the agency.
The practical takeaway
Amazon’s 2023 action followed the FDA’s then-current view that NMN was excluded from the dietary-supplement definition under the drug-preclusion clause. In 2025, the FDA changed that interpretation after concluding that NMN had been marketed as a dietary supplement in the United States before the relevant drug-investigation authorization. The newer agency position is not product approval, a safety guarantee, or an automatic Amazon reinstatement.
For consumers, verify the current listing and full label, and do not treat marketplace availability as a health endorsement. For sellers, check the latest platform rules and product-specific requirements. For readers comparing NMN’s potential benefits, assess clinical evidence separately from this regulatory timeline and seek qualified advice about personal use.
References
- Amazon Restricted Products team. (2023). Seller notice concerning products containing beta-nicotinamide mononucleotide (NMN), including the March 13, 2023 deadline and reinstatement requirements. Copy of Amazon’s notice hosted by the Natural Products Association. View notice.
- U.S. Food and Drug Administration. (2025). Response to citizen petition, Docket No. FDA-2023-P-0872, concerning NMN and section 201(ff)(3)(B) of the FD&C Act. Read FDA response.
- U.S. Food and Drug Administration. Information for Consumers on Using Dietary Supplements. FDA consumer guidance.
- Amazon Seller Central. Food and product safety policy. Current seller policy page.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
